BioTuesdays

Category - Markets

Sol-Gel Logo

HCW starts Sol-Gel at buy; PT $21

H.C. Wainwright initiated coverage of Sol-Gel Technologies (NASDAQ:SLGL) with a “buy” rating and price target of $21. The stock closed at $6.97 on July 13. The company’s lead drug candidates, TWIN and VERED, are...

Kezar Logo

WB starts Kezar Life Sciences at OP and FVE of $25

William Blair initiated coverage of Kezar Life Sciences (NASDAQ:KZR) with an “outperform” rating and fair value estimate of $25. The stock closed at $16.50 on July 13. Analyst Matthew Phipps writes the company’s novel...

Adamas Pharmaceuticals Logo

HCW starts Adamas Pharma at buy; PT $45

H.C. Wainwright launched coverage of Adamas Pharmaceuticals (NASDAQ:ADMS) with a “buy” rating and $45 price target. The stock closed at $27.06 on July 13. Adamas’ lead product, GOCOVRI, was approved in August 2017 in...

Vericel Logo

Ladenburg ups Vericel to buy; PT $13

Ladenburg Thalmann upgraded Vericel (NASDAQ:VCEL) to “buy” from “neutral” and introduced a price target of $13. The stock closed at $9.10 on July 13. “We believe Vericel shares are oversold and would be buyers of the...

Galmed Logo

Stifel starts Galmed Pharma at buy; PT $35

Stifel launched coverage of Galmed Pharmaceuticals (NASDAQ:GLMD) with a “buy” rating and price target of $35. The stock closed at $12.77 on July 12. “We think Galmed’s lead, wholly-owned asset, Aramchol, has...

Syndax Pharma Logo

HCW starts Syndax Pharma at buy; PT $30

H.C. Wainwright initiated coverage of Syndax Pharmaceuticals (NASDAQ:SNDX) with a “buy” rating and a $30 price target. The stock closed at $7.10 on July 11. Analyst Edward White writes that Syndax’s lead candidate...

exicure logo

Ladenburg starts Exicure at buy; PT $18

Ladenburg Thalmann launched coverage of Exicure (OTCQB:XCUR) with a “buy” rating and $18 price target. The stock closed at $5.65 on July 10. Exicure is developing first-in-class spherical nucleic acid (SNA)...

Krystal Biotech Logo

Leerink starts Krystal Biotech at buy; FVE $29

Leerink launched coverage of Krystal Biotech (NASDAQ:KRYS) with a “buy” rating and $29 fair value estimate. The stock closed at $15.07 on July 9. Krystal is developing novel gene therapies for skin diseases, with lead...

Rocket Pharmaceuticals Logo

WB starts Rocket Pharma at OP; FVE $32

William Blair launched coverage of Rocket Pharmaceuticals (NASDAQ:RCKT) with an “outperform” rating and fair value estimate of $32. The stock finished at $19.17 on July 9. Rocket is focused on developing first-in-class...